Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant | Moderna, Inc.

Company testing three existing COVID-19 vaccine booster candidates against the Omicron   variant Company announcing a new variant-specific vaccine candidate against Omicron   (mRNA-1273.529) CAMBRIDGE, Mass. –(BUSINESS WIRE)–Nov. 26, 2021– Moderna, Inc.

Read the full article here

Related Articles